Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIRB 796 BS in Healthy Volunteers
NCT02211157Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2000
- Primary completion
- Jul 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of doramapimod in Crohn's disease, rheumatoid arthritis (RA) and psoriasis (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with clinically relevant changes in laboratory parameters, Number of patients with abnormal findings in electrocardiogram (ECG) and 3 more. Started Mar 2000; status: completed.
02
Drugs
doramapimod
03
Conditions
Crohn's diseaserheumatoid arthritis (RA)psoriasis
Beyond the preview
Go deeper on NCT02211157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211157.